Skip to main content


Fig. 2 | BMC Neurology

Fig. 2

From: Predictive value of early magnetic resonance imaging measures is differentially affected by the dose of interferon beta-1a given subcutaneously three times a week: an exploratory analysis of the PRISMS study

Fig. 2

Time to sustained EDSS progression by ≥4 versus 0 active T2 lesions at 6 months. a Placebo/delayed treatment group; b IFN β-1a 22 μg SC tiw group; c IFN β-1a 44 μg SC tiw group. A Cox proportional hazards model, adjusted for number of relapses in the previous 2 years, age, baseline EDSS score, and baseline burden of disease, was used to estimate hazard ratios and p values. p values are for time to first progression over 4 years. CI: confidence interval; EDSS: Expanded Disability Status Scale; IFN β-1a: interferon beta-1a; SC: subcutaneously; tiw: three times weekly

Back to article page